Larimar Therapeutics, Inc. (LRMR)

NASDAQ: LRMR · IEX Real-Time Price · USD
-0.13 (-3.68%)
Nov 28, 2023, 4:00 PM EST - Market closed

Company Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease.

The company is headquartered in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc.
Larimar Therapeutics logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 26
CEO Dr. Carole S. Ben-Maimon M.D.

Contact Details

Three Bala Plaza East. Suite 506
Bala Cynwyd, Pennsylvania 19004
United States
Phone 844-511-9056

Stock Details

Ticker Symbol LRMR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001374690
CUSIP Number 517125100
ISIN Number US5171251003
Employer ID 20-3857670
SIC Code 2834

Key Executives

Name Position
Dr. Carole S. Ben-Maimon M.D. Chief Executive Officer, President and Director
Michael Celano CPA Secretary and Chief Financial Officer
John Berman Vice President of Finance and Operations
Jennifer Spokes Johansson Vice President of Regulatory Affairs and Counsel
Dr. Nancy M. Ruiz Chief Medical Officer
Francis Michael Conway Vice President and Controller

Latest SEC Filings

Date Type Title
Nov 14, 2023 10-Q Quarterly Report
Nov 14, 2023 8-K Current Report
Oct 3, 2023 8-K Current Report
Aug 18, 2023 SC 13G Statement of acquisition of beneficial ownership by individuals
Aug 14, 2023 8-K Current Report
Aug 10, 2023 10-Q Quarterly Report
Aug 10, 2023 8-K Current Report
Jul 25, 2023 8-K Current Report
Jul 24, 2023 144 Filing
Jul 17, 2023 8-K Current Report